Six-month Outcome of Immunocompromised Severe ARDS Patients Rescued by ECMO
atsjournals.orgRecently diagnosed immunodeficiency is associated with a much better prognosis in ECMO-treated severe ARDS. However, low 6-month survival of our large cohort of immunocompromised patients supports restricting ECMO to patients with realistic oncological/therapeutic prognoses, acceptable functional status and few pre-ECMO mortality-risk factors. We collected demographics, clinical, ECMO-related complications, ICU- and 6-month–outcome data for 203 patients.